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Abstract
Purpose To measure the refractive properties of the healthy
human eye during acute hyperglycemia by means of
Scheimpflug imaging and Hartmann-Shack aberrometry.
Methods Acute hyperglycemia was induced in five healthy
subjects (two males, three females, mean age ±SD
24.8 years ± 4.6) by means of an oral glucose tolerance
test (OGTT) after subcutaneous somatostatin injection.
Before and every 30 minutes after the OGTT, measure-
ments with Scheimpflug imaging and Hartmann-Shack
aberrometry were performed. The main outcome measures
were the thickness and shape of the lens, and the ocular
refractive error and higher order aberrations. The equivalent
refractive index of the lens was calculated from these
parameters. Measurements at baseline and during hyper-
glycemia were analyzed by means of Wilcoxon signed rank
sum tests.
Results During hyperglycemia (mean blood glucose level at
baseline: 4.0 mmol/l; mean maximal blood glucose level:
18.4 mmol/l) no changes could be found in the refractive
properties within the group. In one subject, a hyperopic
shift (0.4 D) was observed, together with a more convex
shape of the anterior lens surface and a decrease in the
equivalent refractive index of the lens.
Conclusions This study shows that hyperglycemia general-
ly does not cause changes in the refractive properties of the
healthy eye. Nevertheless, in one subject a hyperopic shift
accompanied by a change in shape and refractive index of
the lens was measured. This finding could provide an
explanation for the mechanism underlying the refractive
changes that are often observed during hyperglycemia.
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Transient refractive changes, due to a variation in blood
glucose levels, are well-known complications of diabetes
mellitus (DM). Both myopic shifts [2, 6, 10, 23, 31, 36] and
hyperopic shifts [9, 13, 18, 26, 32, 37] have been reported
in patients with DM after several days or weeks of
hyperglycemia. It has been suggested that the predominant
cause of the refractive changes is a change in the thickness
of the lens [16, 17, 19, 25, 29] or shape of the lens [21],
and/or a change in its refractive index [24, 27, 29, 33]. Two
studies have been conducted in which hyperglycemia was
induced under controlled circumstances to investigate
refractive changes during hyperglycemia. Firstly, Gwinup
et al. [15] administered glucose intravenously to ten
patients with DM. A myopic shift of maximal -0.75 D
was measured with autorefractometry. Secondly, Furushima
et al. [11] induced hyperglycemia in seven healthy, young
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Amsterdam, the Netherlandssubjects through somatostatin injections and an oral glucose
load. By means of autorefractometry and ultrasound
biometry a large change in ocular refraction (-2.0 diopters
(D)) and thickness of the lens (1.0 mm) was measured
within 150 minutes after administration of the glucose load
(maximal hyperglycemia: 13.9 mmol/l). The results of these
two studies indicated that induced hyperglycemia can cause
changes in refraction and that these changes appeared to be
larger in healthy subjects.
In the study of Furushima et al. [11], only the thickness
of the lens was measured, and there is no information about
the change in the shape and the refractive index of the lens
due to acute hyperglycemia. Therefore, the aim of our study
was to induce hyperglycemia in healthy subjects under
controlled circumstances, and accurately measure ocular
geometry and refraction by means of corrected Scheimpflug
imaging and Hartmann-Shack aberrometry, in order to
investigate the mechanism underlying refractive changes
during hyperglycemia. From the ocular geometry and
refraction, in combination with the measurement of the
axial length of the eye, it is also possible to calculate the
equivalent refractive index of the lens [4, 5].
Subjects and methods
Five healthy Caucasian subjects (two males and three
females) were recruited for this study. Mean age was
24.8 years (SD ±4.6 and range 21.2–32.6) and mean body
mass index (BMI) was 24.2 kg/m2 (SD ±3.2 and range
21.4 - 29.7). The Medical Ethics Committee of the VU
University Medical Center in Amsterdam approved the
study protocol, and written informed consent was obtained
from all subjects after the nature of the study had been
explained. Subjects with a history of diabetes mellitus (or a
fasting plasma glucose >5.5 mmol/l), a BMI of >30 kg/m2,
visual acuity of <0.5 (Snellen), or a history of ocular
pathology were excluded from the study.
Procedure to induce hyperglycemia
After a 10-hour overnight fast, the subjects received a
subcutaneous injection of 100 µg synthetic somatostatin
(Sandostatin, Novartis, Basel, Switzerland) in order to
suppress the endogenous insulin secretion during glucose
loading. Each subject had an oral glucose tolerance test
(OGTT) (glucose 75 g) 30 minutes after the somatostatin
injection. Blood glucose levels were measured with a blood
glucose analyzer (HemoCue Diagnostics BV, Oisterwijk,
the Netherlands). Endogenous insulin levels were deter-
mined with immunometric assays (Luminescence, Bayer
Diagnostics, Mijdrecht, the Netherlands) in the Laboratory
of Endocrinology of the Department of Clinical Chemistry in
the VUUniversityMedicalCenter.Thesubjectsremainedina
fasting state during the entire procedure.
Measurement of ocular parameters
Before and 120 minutes after the OGTT, 1.0% cyclo-
pentolate and 5.0% phenylephrine eye-drops were admin-
istered to the right eye of the subjects. Hartmann-Shack
aberrometry was performed with an IRX3 aberrometer
(Imagine Eye Optics, Paris, France) and Scheimpflug
imaging was performed with a Topcon SL-45 Scheimpflug
camera, in which the film was replaced by a charge-coupled
device (CCD) camera (St-9XE, SBIG astronomical instru-
ments) with a range of 16 bits of grey values (512×512
pixels, pixel size 20×20 µm, magnification: 1×). Before
and every 30 minutes after the OGTT, three measurements
were made with each apparatus. To obtain accurate
measurements of the shape of the lens, ray-tracing was
performed to correct the Scheimpflug images for the
distortion that is inherent to this technique [4, 5]. By
combining the measurements of the corneal thickness (d1),
the depth of the anterior chamber (ACD), the anterior (R1)
and posterior (R2) radius of the cornea, the lens thickness
(d3) and the anterior (R3) and posterior (R4) radius of the
lens, the axial length of the eye, and ocular refraction, it
was possible to calculate the equivalent refractive index of
the lens (n lens) by means of an iterative process [5]. In
these calculations it was assumed that the refractive indices
of the cornea, aqueous humor, and vitreous do not change,
because in vitro experiments have shown that large changes
in glucose levels induce negligible changes in the refractive
indices of the ocular media [8, 22]. The axial length of the
eye was measured with an IOL-master (Carl Zeiss Inc.,
North America). The equivalent refractive error (ERE) was
calculated as: ERE = sphere + (cylinder/2). Furthermore,
the higher order aberrations (HOA) of each eye were
analyzed for a pupil size of 5.7 mm and they were
summarized in root mean square errors (RMS), including
the third up to the eighth Zernike orders [34]. Furthermore,
the HOA, including the spherical aberrations, were ana-
lyzed separately.
Measurements at baseline and during hyperglycemia
were compared in the whole group by means of Wilcoxon
signed rank sum tests. A refractive change of more than
0.2 D and a change in HOA of more than 0.025 µm were
considered to be meaningful, according to the precision
(defined as 95% confidence interval) for measuring the
ERE and HOA of the aberrometer [3, 30]. Error analysis
indicated that a change in R1, R2, d1, ACD, d3, R3, R4,
and n lens of more than 0.05 mm, 0.05 mm, 0.02 mm,
0.14 mm, 0.15 mm, 0.30 mm and 0.40 mm, and 0.007
respectively, could be considered as significant, according
to the precision of corrected Scheimpflug imaging [4]. In
994 Graefes Arch Clin Exp Ophthalmol (2008) 246:993–998each subject individually, the significance of a change was
determined from the precision of the measurements and the
difference in the ocular parameters at baseline and during
hyperglycemia. P values ≤0.05 were considered statistically
significant.
Results
Figure 1 shows the changes in blood glucose after the
OGTT. In all subjects the mean blood glucose levels rose
from4.0mmol/l(range3.4–4.5mmol/l)to18.4mmol/l(range
16.1–22.0 mmol/l) in 126 minutes (range 90–210 minutes)
after the OGTT. Subject 1 had a delayed elevation of blood
glucoselevel,andthereforethissubjectreceivedasecond75g
oral glucose load at time= 30 minutes. Furthermore, venous
blood samples of subject 1 were taken from the antecubital
vein, which was kept open with 0.9% saline (100 cl).
Endogenous insulin was suppressed by the subcutaneous
injection of somatostatin during the glucose load to a mean
value of 2.1 pmol/l (range 0.4–4.5 pmol/l), and remained
below basal secretion level (<110.0 pmol/l) for 147 minutes
(range 75–270 minutes).
No significant change in ERE was found in the whole
group or in four of the subjects individually. In subject 1, a
hyperopic shift in ERE of 0.4 D and an increase in the
spherical aberration (±SE) from 0.03 ± 0.01 µm at T=0 to
0.11 ± 0.01 µm during hyperglycemia was measured (p<
0.001). The other HOA did not change in subject 1.
Furthermore, there was no significant change in the HOA
separately or the RMS values in the group or in any of the
other subjects individually. No changes in corneal thickness
(d1), corneal shape (R1 and R2), anterior chamber depth
(ACD), lens thickness (d3), or posterior lens shape (R4)
were found in the group or in any of the subjects
individually. In the whole group and in four subjects, no
changes were found in the anterior radius of the lens (R3)
or refractive index (n lens). However, in subject 01, the R3
and n lens changed significantly during hyperglycemia,
compared to normal conditions; R3 decreased from 11.65 to
9.69 mm (mean decrease R3=1.96 mm; p<0.001) and n
lens decreased from 1.436 to 1.422 (mean decrease n lens=
0.014; p=0.003). Figure 2 presents graphs of the normal-
ized ERE, ACD, d3, R3, R4 and n lens of the five subjects.
Figure 3 shows two corrected Scheimpflug images and a
schematic drawing of the lens of subject 1, in order to
illustrate the differences in lens geometry during hypergly-
cemia compared to baseline. In all subjects, both hemato-
logical and ocular parameters normalized within 6 hours
after the OGTT.
Discussion
Refractive changes occur frequently in patients with DM.
The underlying mechanism is still unclear, and therefore the
aim of our study was to measure ocular refraction and
geometry during hyperglycemia, in an attempt to identify a
possible explanation for these refractive changes. The effect
of reproducible hyperglycemia was studied in healthy
subjects without the systemic effects of DM. An OGTT in
combination with a somatostatin injection was used to
induce hyperglycemia. In an earlier study, this was shown
to induce large changes in the refractive error and lens
thickness [11]. Somatostatin inhibits insulin secretion [7],
and to our knowledge there are no reports of refractive
errors or changes in the lens due to this agent.
In general, and in four of the five subjects individually,
no changes in ocular refraction or geometry were found
during hyperglycemia. It could be that a more prolonged
and severe hyperglycemia is needed to induce changes in
refractive error or geometry of the eye. Glucose within the
lens is metabolized via the sorbitol pathway, which consists
of two enzymes that catalyze the conversion of glucose into its
sugar alcohol sorbitol and the further conversion of sorbitol to
fructose. These sugar alcohols tend to accumulate within the
lens, because they penetrate cell membranes poorly. This
accumulation of sugar alcohols causes the lens to swell [12].
This process might have taken longer than the observation
period of the present study. Furthermore, the subjects
measured in our study were young, and it could be that their
lenses, which still have a fast metabolic reaction capacity,
tolerate short hyperglycemic stress without swelling.
The results of our study are not in accordance with the
findings of Furushima et al. [11], who observed a large
myopic shift (-2 D) and a large increase in the thickness of
the lens (1 mm) during hyperglycemia in healthy subjects.
It must be noted that in our study the mean increase in the
blood glucose level was even higher than that of the study
of Furushima et al.. One main difference between our study
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Fig. 1 Changes in blood glucose (BG) levels in the five subjects after
the administration of somatostatin and glucose; the oral glucose load
(75 g) was administered at time=0 minutes
Graefes Arch Clin Exp Ophthalmol (2008) 246:993–998 995and the study by Furushima et al. is the methods that were
used to measure ocular refraction (aberrometry versus
autorefractometry) and ocular geometry (corrected
Scheimpflug imaging versus ultrasound biometry). Howev-
er, the precision of aberrometry and autorefractometry are
comparable for the measurement of defocus, astigmatism
and, consequently, the equivalent refractive error [3, 30,
35]. Furthermore, the precision of corrected Scheimpflug
imaging and ultrasound biometry are comparable as well. It
could be that the difference in ethnicity (Caucasian subjects
in the present study versus Asian subjects in the study by
Furushima et al.) caused the inconsistency between the two
studies, since Asian people generally have a more myopic
ocular refraction than Caucasian subjects [14, 38].
In our study, small but significant changes in ocular
refraction and lens geometry were found in one subject. A
hyperopic shift of 0.4 D was found, in combination with an
increase in anterior convexity of the lens. A combination of
hyperopia and an increase in lens thickness during
hyperglycemia has been described by Kluxen et al. [21],
who found a 6 D hyperopic shift and a 0.4 mm increase in
lens thickness in a diabetic patient with hyperglycemia.
Saito et al. [29] reported hyperopic shifts (1.1 to 4.9 D) and
an increase of approximately 0.2 mm in the thickness of the
lens in five diabetic subjects during hyperglycemia.
Therefore, it has been suggested that hyperglycemia causes
a change in the refractive index of the lens [21, 24, 27, 29,
33]. The results of our study support this hypothesis; in
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Fig. 2 Graphs of the normalized equivalent refractive error (ERE),
lens thickness (d3), anterior chamber depth (ACD), anterior (R3) and
posterior (R4) radius of the lens, and the refractive index of the lens
(n lens) of the five subjects. Data are normalized by subtracting the
value at baseline from the measured value in each subject. In subject
01 a hyperopic shift of 0.4 D, an increase in R3 and decrease in n lens
were found during hyperglycemia at T=240 minutes (p<0.01). The
oral glucose load was administered at T=0
996 Graefes Arch Clin Exp Ophthalmol (2008) 246:993–998subject 1, a decrease in the equivalent refractive index of
the lens was calculated during hyperglycemia. It could be
suggested that if the change in the shape of the lens is
small, hyperopia will predominate during hyperglycemia
due to a decrease in the refractive index of the lens.
Alternatively, if the change in the shape of the lens is large
in comparison to the decrease in the refractive index of the
lens, the overall refractive error will result in myopia. The
controversy in the literature with regard to refractive
changes during hyperglycemia could be explained by this
underlying mechanism of a balance between changes in the
shape or the refractive index of the lens, which eventually
determine the overall refractive outcome [20, 23, 28, 37].
It is surprising that a change in refraction and ocular
parameters could be determined in only one subject. It must
be noted that the procedures for inducing hyperglycemia
and monitoring blood glucose were, to some extent,
different for subject 1 compared to the other subjects.
Because of a delayed elevation in blood glucose level, a
second oral glucose load (150 g instead of 75 g glucose)
was administered. Nevertheless, the maximum blood
glucose value of subject 1 did not exceed that of the other
subjects, and the endogenous insulin level was adequately
suppressed during the glucose loading. Furthermore, in
order to obtain sufficient blood samples, 0.9% saline had to
be administered to keep the antecubital vein open.
Therefore, it could not be excluded that the administration
of saline contributed to the refractive change and alterations
in the lens of subject 1. However, no studies have yet
reported any refractive change due to saline administration.
The change in refractive error in patients with hypergly-
cemia could also be caused by a change in the shape of the
cornea. However, previous research has shown that hyper-
glycemia has no influence on the shape of the anterior
corneal surface [10, 24, 29, 32]. The results of our study
also agree with these findings. No change in the anterior or
posterior corneal radius was found during hyperglycemia.
Therefore, the cornea does not seem to play a role in the
explanation of refractive changes during hyperglycemia.
This also applies for the higher order aberrations. Applegate
et al. [1] reported that an increase in the higher order
aberrations could cause a decrease in visual acuity.
However, no changes in the higher order aberrations were
found in any of the subjects in our study. Therefore, it can
be assumed that blurred vision in hyperglycemia cannot be
explained by changes in the higher order aberrations of the
eye.
In sum, the results of this study show that induced
hyperglycemia generally does not cause changes in the
refractive properties of the healthy human eye. However,
there were interindividual variations, as illustrated by
subject 1, who had a hyperopic shift of refraction and a
change in shape and equivalent refractive index of the lens
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Fig. 3 Corrected Scheimpflug images of the right eye of subject 1. a
At baseline time=0 minutes, the shape of the cornea and lens are
indicated with a solid line. b During hyperglycemia at time=240
minutes after the first oral glucose load, the shape of the cornea and
lens are indicated with a line of dashes. c A drawing of the changes in
the shape of the lens in hyperglycemic condition (line of dashes)
compared to the normal condition (solid line)
Graefes Arch Clin Exp Ophthalmol (2008) 246:993–998 997during hyperglycemia. This could provide an explanation
for the mechanism underlying the refractive changes often
experienced by patients with DM and hyperglycemia.
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